Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1719053

registered interest
date	17/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Methylphenidate
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with Janssen on the adequacy of supply of the ADHD medication Concerta XL.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	26903
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>The Department has been working hard with industry to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, including Concerta XL tablets, which are affecting the United Kingdom and other countries around the world. This has involved asking that suppliers expedite deliveries to boost supplies of these important medicines, and addressing regulatory issues to ensure continuity of supply. As a result of our ongoing activity and intensive work, some issues have been resolved. We expect the disruptions to the supply of Concerta XL tablets to be resolved in May 2024.</p><p>The Department held a roundtable with all suppliers of methylphenidate prolonged-release tablet suppliers, including Janssen, in April 2024, to discuss the challenges they are facing, what they are doing, and what needs to be done to address these issues.</p><p>We have worked closely with specialist clinicians during this time to develop management advice for the National Health Service. The guidance includes advice for ADHD service providers and specialists to offer rapid response to primary care teams seeking urgent advice for the management of patients. This includes those known to be at a higher risk of adverse impact because of these shortages.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 26904 question first answered 23/05/2024 15:25:17 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4523 label Biography information for Catherine West

1719054

registered interest
date	17/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Methylphenidate
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure patients have access to Concerta XL.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	26904
answer	answer is ministerial correction date of answer 23/05/2024 answer text <p>The Department has been working hard with industry to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, including Concerta XL tablets, which are affecting the United Kingdom and other countries around the world. This has involved asking that suppliers expedite deliveries to boost supplies of these important medicines, and addressing regulatory issues to ensure continuity of supply. As a result of our ongoing activity and intensive work, some issues have been resolved. We expect the disruptions to the supply of Concerta XL tablets to be resolved in May 2024.</p><p>The Department held a roundtable with all suppliers of methylphenidate prolonged-release tablet suppliers, including Janssen, in April 2024, to discuss the challenges they are facing, what they are doing, and what needs to be done to address these issues.</p><p>We have worked closely with specialist clinicians during this time to develop management advice for the National Health Service. The guidance includes advice for ADHD service providers and specialists to offer rapid response to primary care teams seeking urgent advice for the management of patients. This includes those known to be at a higher risk of adverse impact because of these shortages.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 26903 question first answered 23/05/2024 15:25:17 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4523 label Biography information for Catherine West

1715607

registered interest
date	02/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Carbamazepine
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with Novartis on the adequacy of supply of the epilepsy medication Tegretol.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	24690
answer	answer is ministerial correction date of answer 09/05/2024 answer text <p>The Department has been working intensively to address issues with the supply of some epilepsy medications, and as a result we have helped to resolve issues with Tegretol 200 milligram and 400 milligram prolonged release tablets, and Tegretol 100 milligram immediate release tablets. We are aware of a shortage of Tegretol 100 milligram/5 millilitre liquid, but have been advised that resupplies are expected this month. We are continuing to work closely with manufacturers, including Novartis, to help ensure the continued supply of these medicines for patients in the United Kingdom, for example by asking suppliers to expedite deliveries.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals, so they can advise and support their patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 09/05/2024 13:04:37 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4523 label Biography information for Catherine West

1715632

registered interest
date	02/05/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Phramacy: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to help tackle shortages of medicines in pharmacies.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	24691
answer	answer is ministerial correction date of answer 09/05/2024 answer text <p>The Department has a responsibility to work with United Kingdom medicine license holders, to help ensure continuity of supply. We monitor and manage medicine supply at a national level, so that stocks remain available to meet regional and local demand. There are approximately 14,000 medicines licensed for supply in the UK, and the overwhelming majority are in good supply. The medicine supply chain is complex, global, and highly regulated, and supply issues can be caused by a range of factors. For example, suppliers can encounter manufacturing problems, difficulty accessing raw materials, and surges in demand. These are commonly cited as the drivers of recent supply issues, which have affected many countries, not just the UK.</p><p>Whilst we can’t always prevent supply issues, we have a range of well-established tools and processes to mitigate risks to patients at a national level. These include close and regular engagement with suppliers, use of alternative strengths or forms of a medicine to allow patients to remain on the same product, expediting regulatory procedures, sourcing unlicensed imports from abroad, adding products to the restricted exports and hoarding list, use of Serious Shortage Protocols, and issuing National Health Service communications to provide management advice and information on the issue to healthcare professionals including pharmacists, so they can advise and support their patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 09/05/2024 12:56:25 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4523 label Biography information for Catherine West

1697523

registered interest
date	20/03/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Postural Tachycardia Syndrome
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking to support people with postural tachycardia syndrome.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	19656
answer	answer is ministerial correction date of answer 27/03/2024 answer text <p>Services for postural tachycardia syndrome (PoTS) are locally commissioned and, as such, it is the responsibility of the local commissioning teams within integrated care boards to ensure that their locally commissioned services meet the needs of their local population.</p><p>The National Institute for Health and Care Excellence has produced a clinical knowledge summary, last revised in November 2023, which outlines the method healthcare professionals should follow for diagnosing PoTS. This summary is available at the following link:</p><p><a href="https://cks.nice.org.uk/topics/blackouts-syncope/diagnosis/assessment/" target="_blank">https://cks.nice.org.uk/topics/blackouts-syncope/diagnosis/assessment/</a></p><p>Clinical knowledge summaries are evidence-based summaries designed to support healthcare professionals in primary care, by providing them with a readily accessible summary of the current evidence base and practical advice on best practice.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 27/03/2024 10:11:12 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4523 label Biography information for Catherine West

1689362

registered interest
date	16/02/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Genomics: China
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has plans to (a) review and (b) update guidance on partnerships between private healthcare providers and Chinese genomic companies.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	14261
answer	answer is ministerial correction date of answer 26/02/2024 answer text <p>As part of the new UK Biological Security Strategy, the Government is assessing how we can minimise the risks from biological data to protect our burgeoning bioeconomy, without stifling innovation, and build confidence in sharing personal data to improve health outcomes in the United Kingdom and across the world. The Office for Life Sciences is conducting this work at pace.</p><p>The Research Collaboration Advice Team, which has been operating since March 2022 as part of the Department for Science, Innovation and Technology, provides advice to UK stakeholders about research collaborations. In 2020, Universities UK, with support from the Government, the Centre for the Protection of National Infrastructure and the National Cyber Security Centre, published guidelines to help universities tackle security risks related to international collaboration. Universities UK continues to evaluate the effectiveness of their guidelines, updating it when necessary.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 26/02/2024 10:04:02 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4523 label Biography information for Catherine West

1683345

registered interest
date	18/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Sunscreens: VAT
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment she has made with the Chancellor of the Exchequer of the potential impact of removing VAT from factor 30+ sunscreen on the level of incidence of skin cancer.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	10499
answer	answer is ministerial correction date of answer 25/01/2024 answer text <p>Whilst the Department has not made a specific assessment, under the current VAT rules, sun protection products are subject to the standard rate of VAT. High-factor sunscreen is on the National Health Service prescription list for certain conditions and therefore is provided free of VAT when dispensed by a pharmacist. While HM Treasury keeps all taxes under review, there are no plans to make changes. Representations on changes to the VAT system will be considered through the normal fiscal event process.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 25/01/2024 15:53:33 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4523 label Biography information for Catherine West

1681815

registered interest
date	12/01/2024
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescription Drugs: Internet
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps she is taking with Cabinet colleagues to help tackle the sale of prescription-only drugs to patients without a prescription through illicit websites.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	9352
answer	answer is ministerial correction date of answer 18/01/2024 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is the regulator in the United Kingdom for human medicines and is responsible for enforcing the Human Medicines Regulations 2012. The MHRA has identified the illegal sale and supply of human medicines as a global challenge. This includes the sale of prescription drugs from unregulated sources. Criminal gangs, often based overseas, advertise medicines through illicit websites resembling those of legitimate pharmacies, while others exploit online marketplaces or sell social media platforms.</p><p>The MHRA has a dedicated Criminal Enforcement Unit (CEU) that works with partners across government and policing to prevent and disrupt this illegal trade and to bring to justice those involved. The CEU monitors online channels for evidence of illegal activity and takes proportionate regulatory action. This includes using the full range of the Agency’s powers to investigate and prosecute offenders where necessary and appropriate. The unit also works to remove illegally trading websites and remove criminal profits from offenders. Through its #Fakemeds communications campaign the MHRA also provides quick and easy tools to help the public avoid buying illegally traded medicines when they shop online.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/01/2024 11:53:22 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4523 label Biography information for Catherine West

1678150

registered interest
date	14/12/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Anaesthesia Associates and Physician Associates: Regulation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has made a recent assessment of the potential merits of regulating NHS (a) physician and (b) anaesthesia associates through the Health and Care Professions Council.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	7073
answer	answer is ministerial correction date of answer 19/12/2023 answer text <p>The assessment of the appropriate regulatory body for physician associate (PA) and anaesthesia associate (AA) regulation was completed in 2019. On 7 February 2019, the Government published its response to the consultation on the Regulation of Medical Associate Professions in the United Kingdom, confirming its decision to introduce statutory regulation for PAs and AAs. Most respondents to the consultation were in favour of the General Medical Council (GMC) taking on regulation.</p><p>Following further work by the Department, on 18 July 2019, the Government announced that it would be asking the GMC to regulate both roles. No further assessments have been made of the potential merits of the Health and Care Professions Council (HCPC) regulating PAs and AAs and there have been no recent discussions with the HCPC on this matter.</p><p>Regulation by the GMC will mean that the organisation will have responsibility and oversight of all three professions allowing them to take a holistic approach to the education, training, and standards of the roles. This will enable a more coherent and co-ordinated approach to regulation and, by making it easier for employers, patients, and the public to understand the relationship between these roles and doctors, help to embed them in the workforce.</p><p>On 13 December 2023, the Department laid draft legislation in both Houses and in the Scottish Parliament that will empower the GMC to commence regulation for the two roles by the end of 2024.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 7074 7075 question first answered 19/12/2023 16:08:12 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4523 label Biography information for Catherine West

1678151

registered interest
date	14/12/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Anaesthesia Associates and Physician Associates: Regulation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether she has had recent discussions with the Health and Care Professions Council on the regulation of NHS (a) physician and (b) anaesthesia associates.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	7074
answer	answer is ministerial correction date of answer 19/12/2023 answer text <p>The assessment of the appropriate regulatory body for physician associate (PA) and anaesthesia associate (AA) regulation was completed in 2019. On 7 February 2019, the Government published its response to the consultation on the Regulation of Medical Associate Professions in the United Kingdom, confirming its decision to introduce statutory regulation for PAs and AAs. Most respondents to the consultation were in favour of the General Medical Council (GMC) taking on regulation.</p><p>Following further work by the Department, on 18 July 2019, the Government announced that it would be asking the GMC to regulate both roles. No further assessments have been made of the potential merits of the Health and Care Professions Council (HCPC) regulating PAs and AAs and there have been no recent discussions with the HCPC on this matter.</p><p>Regulation by the GMC will mean that the organisation will have responsibility and oversight of all three professions allowing them to take a holistic approach to the education, training, and standards of the roles. This will enable a more coherent and co-ordinated approach to regulation and, by making it easier for employers, patients, and the public to understand the relationship between these roles and doctors, help to embed them in the workforce.</p><p>On 13 December 2023, the Department laid draft legislation in both Houses and in the Scottish Parliament that will empower the GMC to commence regulation for the two roles by the end of 2024.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 7073 7075 question first answered 19/12/2023 16:08:12 answering member 4044 label Biography information for Andrew Stephenson
tabling member	4523 label Biography information for Catherine West